- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Grant Infrastructure Status to Bulk Drug Industry : CII Report on API sector
New Delhi: While Indian pharmaceutical industry has rightfully gained the epithet 'pharmacy to the world', it has also become highly import dependant for its key starting material (KSM), intermediates and active pharmaceutical ingredients (APIs).
In this context, CII in partnership with KPMG has released the report titled "Indian API Industry- Reaching the Full Potential". This study lays down pillars required to make India a manufacturing hub for APIs and making the nation self-sufficient.
"The recently launched Government schemes to promote API (bulk drug) through clusters and Production Linked Incentive program will help support the 'Make in India' initiative for domestic manufacturing. However, challenges around land acquisition, ease of doing business, environmental clearances, taxation, and R&D need to be resolved for India to become a global API hub," says Mr G V Prasad, Chairman, CII National Committee on Pharmaceuticals and Co-Chairman and Managing Director Dr. Reddy's Laboratory Limited.
As a short and mid-term measure, CII recommends to grant "infrastructure status" to the bulk drug industry and create common minimum infrastructure facilities in the form of 4-5 integrated large-scale clusters to manufacture critical APIs/Intermediates and KSMs to achieve economies of scale.
CII further recommends government support on capital intensive fermentation based API industry and dedicated clusters for the same. Single window clearance system for establishing an API manufacturing unit and further product development, priority environmental clearances for APIs with definite timeline, soft loans with long repayment periods, 20-25% percent incentives on API Manufacturing are imperative.
It is also recommended to reinstate weighted tax deductions of 200% on expenditure on R&D which, in-turn, will help boost innovation in the country.
As long term strategy, this report recommends increased collaboration between industry and academia, subsidies and incentives for technology modernization and adoption of green technology.
Over the past two decades, India's reliance has grown for imports of low-cost intermediates and APIs. Over-dependence on imports has increased the threat to the nation's health security. The COVID-19 crisis has brought forth the need for India to have its own strengths and supplies of API for its robust pharma sector and the Government's recently approved package of INR 9,940 crore shall boost the domestic production of bulk drugs and exports.
The report provides an in-depth analysis of overall cost of API production in China, which is 20-30% lower than in India. It also compares inter industry incentivization schemes and models including sectors like automobile, electronics, biotechnology, textile and IT/ITeS. This report will be useful in drafting fine print and models of incentivization for recently announced scheme by Department of Pharmaceuticals.
The report articulates strengths of the Indian API industry along with key challenges of low fermentation capacity, high cost of utilities such as electricity, steam, water, brine, heating, ventilation and air conditioning, limited funding for R&D in the bulk drug industry and technology upgradation and absence of large scale API clusters.
Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She is a member of the Association of Healthcare Journalists. She can be contacted at meghna@medicaldialogues.in. Contact no. 011-43720751